{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,17]],"date-time":"2026-09-17T08:03:22Z","timestamp":1789632202094,"version":"build-2803163510"},"reference-count":81,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Current Opinion in Pharmacology"],"published-print":{"date-parts":[[2026,12]]},"DOI":"10.1016\/j.coph.2026.102665","type":"journal-article","created":{"date-parts":[[2026,8,27]],"date-time":"2026-08-27T16:31:38Z","timestamp":1787848298000},"page":"102665","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Pharmacological insights into fluvoxamine maleate: \u03c31 receptor agonism, multimodal mechanisms, and therapeutic repositioning"],"prefix":"10.1016","volume":"91","author":[{"given":"Chirag","family":"Sharma","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sheenam","family":"Sharma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rishabh","family":"Chaudhary","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Satish","family":"Kumar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Seema","family":"Bansal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anroop","family":"Nair","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sumeet","family":"Gupta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.coph.2026.102665_bib1","doi-asserted-by":"crossref","first-page":"2888","DOI":"10.3390\/ijms19102888","article-title":"Eradicating suicide at its roots: preclinical bases and clinical evidence of the efficacy of ketamine in the treatment of suicidal behaviors","volume":"19","author":"De Berardis","year":"2018","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.coph.2026.102665_bib2","doi-asserted-by":"crossref","first-page":"119","DOI":"10.2174\/187152711794488674","article-title":"The emerging role of melatonin agonists in the treatment of major depression: focus on agomelatine","volume":"10","author":"De Berardis","year":"2011","journal-title":"CNS Neurol Disord: Drug Targets"},{"key":"10.1016\/j.coph.2026.102665_bib3","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2021.652688","article-title":"Fluvoxamine: a review of its mechanism of action and its role in COVID-19","volume":"12","author":"Sukhatme","year":"2021","journal-title":"Front Pharmacol"},{"key":"10.1016\/j.coph.2026.102665_sref4","doi-asserted-by":"crossref","first-page":"700","DOI":"10.3390\/ph18050700","article-title":"Repurposing Sigma-1 receptor-targeting drugs for neurodegenerative disorders: mechanistic insights and therapeutic opportunities","volume":"18","author":"Eskandari","year":"2025","journal-title":"Pharmaceuticals"},{"key":"10.1016\/j.coph.2026.102665_sref5","doi-asserted-by":"crossref","first-page":"711","DOI":"10.3390\/ph18050711","article-title":"An overview of the systematic reviews about the efficacy of fluvoxamine on depression","volume":"18","author":"Dieckmann","year":"2025","journal-title":"Pharmaceuticals"},{"key":"10.1016\/j.coph.2026.102665_sref6","doi-asserted-by":"crossref","first-page":"353","DOI":"10.3390\/ph18030353","article-title":"The efficacy of fluvoxamine in anxiety disorders and obsessive-compulsive disorder: an overview of systematic reviews and meta-analyses","volume":"18","author":"Haddad","year":"2025","journal-title":"Pharmaceuticals"},{"key":"10.1016\/j.coph.2026.102665_bib7","doi-asserted-by":"crossref","first-page":"313","DOI":"10.2165\/00003495-198632040-00002","article-title":"Fluvoxamine","volume":"32","author":"Benfield","year":"1986","journal-title":"Drugs"},{"issue":"Suppl 1","key":"10.1016\/j.coph.2026.102665_bib8","doi-asserted-by":"crossref","first-page":"26","DOI":"10.2165\/00003088-199500291-00006","article-title":"Fluvoxamine","volume":"29","author":"Wagner","year":"1995","journal-title":"Clin Pharmacokinet"},{"key":"10.1016\/j.coph.2026.102665_bib9","doi-asserted-by":"crossref","first-page":"1206","DOI":"10.1016\/S0149-2918(08)80047-1","article-title":"Clinically relevant pharmacokinetic drug interactions with second-generation antidepressants: an update","volume":"30","author":"Spina","year":"2008","journal-title":"Clin Ther"},{"key":"10.1016\/j.coph.2026.102665_sref10","doi-asserted-by":"crossref","first-page":"280","DOI":"10.3390\/ph17030280","article-title":"Pharmacokinetics and pharmacodynamics: a comprehensive analysis of the absorption, distribution, metabolism, and excretion of psychiatric drugs","volume":"17","author":"Zakaraya","year":"2024","journal-title":"Pharmaceuticals"},{"key":"10.1016\/j.coph.2026.102665_bib11","doi-asserted-by":"crossref","first-page":"3817","DOI":"10.5958\/0974-360X.2020.00676.9","article-title":"Fabrication and characterization of single layer osmotic pump (SCOP) by solubility modulation approach for fluvoxamine maleate","volume":"13","author":"Umaretiya","year":"2020","journal-title":"Res J Pharm Technol"},{"key":"10.1016\/j.coph.2026.102665_bib12","doi-asserted-by":"crossref","first-page":"4134","DOI":"10.1016\/j.arabjc.2019.06.001","article-title":"Degradation kinetics of fluvoxamine in buffer solutions: in silico ADMET profiling and identification of degradation products by LC-MS\/ESI","volume":"13","author":"Naz","year":"2020","journal-title":"Arab J Chem"},{"key":"10.1016\/j.coph.2026.102665_bib13","first-page":"1458","article-title":"Brain penetrance and pharmacokinetic evaluation of intranasally administered fluvoxamine nanoformulation","volume":"47","author":"Alexander","year":"2021","journal-title":"Drug Dev Ind Pharm"},{"key":"10.1016\/j.coph.2026.102665_bib14","doi-asserted-by":"crossref","first-page":"301","DOI":"10.2147\/NDT.S3301","article-title":"Management of obsessive-compulsive disorder with fluvoxamine extended release","volume":"5","author":"Fontenelle","year":"2009","journal-title":"Neuropsychiatric Dis Treat"},{"key":"10.1016\/j.coph.2026.102665_bib15","doi-asserted-by":"crossref","first-page":"177","DOI":"10.2165\/00003088-199324020-00006","article-title":"Pharmacokinetics of fluvoxamine in patients with liver cirrhosis after single-dose oral administration","volume":"24","author":"van Harten","year":"1993","journal-title":"Clin Pharmacokinet"},{"issue":"Suppl 1","key":"10.1016\/j.coph.2026.102665_bib16","doi-asserted-by":"crossref","first-page":"1","DOI":"10.2165\/00003088-199500291-00003","article-title":"Overview of the pharmacokinetics of fluvoxamine","volume":"29","author":"van Harten","year":"1995","journal-title":"Clin Pharmacokinet"},{"key":"10.1016\/j.coph.2026.102665_bib17","doi-asserted-by":"crossref","first-page":"175","DOI":"10.2165\/00003088-199427030-00002","article-title":"Clinical pharmacokinetics of fluvoxamine","volume":"27","author":"Perucca","year":"1994","journal-title":"Clin Pharmacokinet"},{"key":"10.1016\/j.coph.2026.102665_bib18","doi-asserted-by":"crossref","first-page":"1211","DOI":"10.1016\/0006-2952(93)90272-X","article-title":"Fluvoxamine is a potent inhibitor of cytochrome P4501A2","volume":"45","author":"Br\u00f8sen","year":"1993","journal-title":"Biochem Pharmacol"},{"key":"10.1016\/j.coph.2026.102665_bib19","doi-asserted-by":"crossref","first-page":"640","DOI":"10.4088\/JCP.v64n0604","article-title":"A double-blind, placebo-controlled study of the efficacy and safety of controlled-release fluvoxamine in patients with obsessive-compulsive disorder","volume":"64","author":"Hollander","year":"2003","journal-title":"J Clin Psychiatry"},{"key":"10.1016\/j.coph.2026.102665_bib20","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1038\/s41586-020-2286-9","article-title":"A SARS-CoV-2 protein interaction map reveals targets for drug repurposing","volume":"583","author":"Gordon","year":"2020","journal-title":"Nature"},{"key":"10.1016\/j.coph.2026.102665_bib21","article-title":"Fluvoxamine as an anti-COVID-19 therapeutic: mechanism of action and current evidence","volume":"138","author":"Brimson","year":"2021","journal-title":"Biomed Pharmacother"},{"key":"10.1016\/j.coph.2026.102665_bib22","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1046\/j.1365-2125.1998.00670.x","article-title":"Non-linear fluvoxamine disposition","volume":"45","author":"Spigset","year":"1998","journal-title":"Br J Clin Pharmacol"},{"key":"10.1016\/j.coph.2026.102665_bib23","doi-asserted-by":"crossref","first-page":"925","DOI":"10.2165\/00003495-200060040-00006","article-title":"Fluvoxamine: an updated review of its use in the management of adults with anxiety disorders","volume":"60","author":"Figgitt","year":"2000","journal-title":"Drugs"},{"key":"10.1016\/j.coph.2026.102665_bib24","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1016\/j.schres.2019.05.033","article-title":"Effect of fluvoxamine augmentation and smoking on clozapine serum concentrations","volume":"210","author":"Augustin","year":"2019","journal-title":"Schizophr Res"},{"key":"10.1016\/j.coph.2026.102665_sref25","doi-asserted-by":"crossref","DOI":"10.1002\/rmv.2501","article-title":"Evaluating fluvoxamine for the outpatient treatment of COVID-19: a systematic review and meta-analysis","volume":"34","author":"Deng","year":"2024","journal-title":"Rev Med Virol"},{"key":"10.1016\/j.coph.2026.102665_bib26","doi-asserted-by":"crossref","first-page":"408","DOI":"10.34172\/apb.2023.045","article-title":"Fluvoxamine mediates specific, early, and delayed SARS-CoV-2 protection through antioxidant and cytoprotective pathways via Sigma-1 receptor agonism","volume":"13","author":"Papadopoulos","year":"2023","journal-title":"Adv Pharmaceut Bull"},{"key":"10.1016\/j.coph.2026.102665_bib27","first-page":"240","article-title":"Selective serotonin reuptake inhibitors in depression","volume":"389","author":"Geddes","year":"2017","journal-title":"Lancet"},{"key":"10.1016\/j.coph.2026.102665_bib28","doi-asserted-by":"crossref","first-page":"2059","DOI":"10.1056\/NEJMcp1502514","article-title":"Generalized anxiety disorder","volume":"373","author":"Stein","year":"2015","journal-title":"N Engl J Med"},{"key":"10.1016\/j.coph.2026.102665_bib29","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1038\/nrn2284","article-title":"Targeting the murine serotonin transporter: insights into human neurobiology","volume":"9","author":"Murphy","year":"2008","journal-title":"Nat Rev Neurosci"},{"key":"10.1016\/j.coph.2026.102665_sref30","first-page":"6983","article-title":"Sigma-1 pharmacology in neurodegenerative and neuropsychiatric disorders","volume":"25","author":"Kim","year":"2024","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.coph.2026.102665_bib31","doi-asserted-by":"crossref","first-page":"1116","DOI":"10.1016\/j.biopsych.2006.02.013","article-title":"A neurotrophic model for stress-related mood disorders","volume":"59","author":"Duman","year":"2006","journal-title":"Biol Psychiatry"},{"key":"10.1016\/j.coph.2026.102665_bib32","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1038\/nrneurol.2017.99","article-title":"ER stress and the unfolded protein response in neurodegeneration","volume":"13","author":"Hetz","year":"2017","journal-title":"Nat Rev Neurol"},{"key":"10.1016\/j.coph.2026.102665_sref33","doi-asserted-by":"crossref","DOI":"10.3389\/fpsyt.2024.1415905","article-title":"Enduring effects of psychotherapy, antidepressants and their combination for depression: a systematic review and meta-analysis","volume":"15","author":"Voderholzer","year":"2024","journal-title":"Front Psychiatr"},{"key":"10.1016\/j.coph.2026.102665_bib34","doi-asserted-by":"crossref","first-page":"894","DOI":"10.1038\/nature07455","article-title":"Animal models of depression","volume":"455","author":"Krishnan","year":"2008","journal-title":"Nature"},{"key":"10.1016\/j.coph.2026.102665_bib35","first-page":"497","article-title":"Prescribing patterns of antidepressants in Europe","volume":"18","author":"Bauer","year":"2008","journal-title":"Eur Neuropsychopharmacol"},{"key":"10.1016\/j.coph.2026.102665_bib36","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0002558","article-title":"Potentiation of nerve growth factor-induced neurite outgrowth by fluvoxamine: role of Sigma-1 receptors, IP3 receptors and cellular signaling pathways","volume":"3","author":"Nishimura","year":"2008","journal-title":"PLoS One"},{"key":"10.1016\/j.coph.2026.102665_bib37","doi-asserted-by":"crossref","first-page":"1072","DOI":"10.1016\/j.pnpbp.2008.01.005","article-title":"Fluvoxamine as a Sigma-1 receptor agonist improved cognitive impairments in a patient with schizophrenia","volume":"32","author":"Iyo","year":"2008","journal-title":"Prog Neuropsychopharmacol Biol Psychiatry"},{"key":"10.1016\/j.coph.2026.102665_bib38","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1016\/j.amjmed.2005.03.044","article-title":"Selective serotonin reuptake inhibitors and increased bleeding risk: are we missing something?","volume":"119","author":"Serebruany","year":"2006","journal-title":"Am J Med"},{"key":"10.1016\/j.coph.2026.102665_bib39","doi-asserted-by":"crossref","first-page":"47","DOI":"10.31887\/DCNS.2007.9.1\/dhalperin","article-title":"Influence of antidepressants on hemostasis","volume":"9","author":"Halperin","year":"2007","journal-title":"Dialogues Clin Neurosci"},{"key":"10.1016\/j.coph.2026.102665_bib40","doi-asserted-by":"crossref","first-page":"417","DOI":"10.4306\/pi.2013.10.4.417","article-title":"Beneficial effects of Sigma-1 agonist fluvoxamine for tardive dyskinesia and tardive akathisia in patients with schizophrenia: report of three cases","volume":"10","author":"Albayrak","year":"2013","journal-title":"Psychiatry Investig"},{"key":"10.1016\/j.coph.2026.102665_bib41","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/j.ejphar.2003.12.008","article-title":"Chronic fluoxetine-induced desensitization of 5-HT1A and 5-HT1B autoreceptors: regional differences and effects of WAY-100635","volume":"486","author":"Newman","year":"2004","journal-title":"Eur J Pharmacol"},{"key":"10.1016\/j.coph.2026.102665_bib42","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1177\/0269881108089876","article-title":"Efficacy, tolerability and side-effect profile of fluvoxamine for major depression: meta-analysis","volume":"23","author":"Omori","year":"2009","journal-title":"J Psychopharmacol"},{"key":"10.1016\/j.coph.2026.102665_bib43","first-page":"507","article-title":"Human circadian rhythms and melatonin","volume":"23","author":"Skene","year":"2006","journal-title":"Chronobiol Int"},{"key":"10.1016\/j.coph.2026.102665_bib44","doi-asserted-by":"crossref","first-page":"482","DOI":"10.1111\/j.1368-5031.2006.00865.x","article-title":"Tolerability and safety of fluvoxamine and other antidepressants","volume":"60","author":"Westenberg","year":"2006","journal-title":"Int J Clin Pract"},{"key":"10.1016\/j.coph.2026.102665_bib45","first-page":"415","article-title":"Fluvoxamine-theophylline interaction: gap between in vitro and in vivo inhibition constants toward cytochrome P4501A2","volume":"70","author":"Yao","year":"2001","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.coph.2026.102665_bib46","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1016\/0165-0327(92)90082-H","article-title":"Effects of acute and chronic treatment with fluvoxamine on extracellular and platelet serotonin in the blood of major depressive patients: relationship to clinical improvement","volume":"25","author":"Celada","year":"1992","journal-title":"J Affect Disord"},{"key":"10.1016\/j.coph.2026.102665_sref47","article-title":"A systematic review and meta-analysis investigating dose and time of fluvoxamine treatment efficacy for COVID-19 clinical deterioration, death, and long-COVID complications","volume":"14","author":"Prasanth","year":"2024","journal-title":"Sci Rep"},{"key":"10.1016\/j.coph.2026.102665_bib48","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1038\/nrn2868","article-title":"Sleep and circadian rhythm disruption in psychiatric disorders","volume":"11","author":"Wulff","year":"2010","journal-title":"Nat Rev Neurosci"},{"key":"10.1016\/j.coph.2026.102665_sref49","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1111\/pcn.13811","article-title":"Efficacy and safety of each class of sleep medication for major depressive disorder with insomnia symptoms: a systematic review and meta-analysis of double-blind randomized controlled trials","volume":"79","author":"Maruki","year":"2025","journal-title":"Psychiatr Clin Neurosci"},{"issue":"Suppl 1","key":"10.1016\/j.coph.2026.102665_bib50","doi-asserted-by":"crossref","first-page":"1","DOI":"10.2165\/00003088-199700321-00003","article-title":"Clinically relevant pharmacology of selective serotonin reuptake inhibitors","volume":"32","author":"Preskorn","year":"1997","journal-title":"Clin Pharmacokinet"},{"key":"10.1016\/j.coph.2026.102665_bib51","first-page":"107","article-title":"Pharmacology of antidepressants: update and new developments","volume":"30","author":"Owens","year":"1994","journal-title":"Psychopharmacol Bull"},{"issue":"Suppl 3","key":"10.1016\/j.coph.2026.102665_bib52","doi-asserted-by":"crossref","first-page":"S81","DOI":"10.1016\/S0924-977X(99)00030-9","article-title":"Mechanisms of action of selective serotonin reuptake inhibitors in the treatment of psychiatric disorders","volume":"9","author":"Nutt","year":"1999","journal-title":"Eur Neuropsychopharmacol"},{"key":"10.1016\/j.coph.2026.102665_sref53","article-title":"Fluvoxamine ameliorates the damage to the neuro-behavioral status of rats caused by the administration of valproic acid by preventing cognitive memory deficits and decreased hippocampal cellular proliferation","volume":"16","author":"Elbeltagy","year":"2024","journal-title":"Cureus"},{"key":"10.1016\/j.coph.2026.102665_bib54","doi-asserted-by":"crossref","first-page":"291","DOI":"10.2147\/NSS.S220947","article-title":"The effect of fluvoxamine on sleep architecture of depressed patients with insomnia: an 8-week, open-label, baseline-controlled study","volume":"11","author":"Hao","year":"2019","journal-title":"Nat Sci Sleep"},{"key":"10.1016\/j.coph.2026.102665_bib55","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1007\/s002139900362","article-title":"Sleep changes during long-term treatment of depression with fluvoxamine: a home-based study","volume":"149","author":"Wilson","year":"2000","journal-title":"Psychopharmacology (Berl)"},{"key":"10.1016\/j.coph.2026.102665_bib56","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1007\/s002280050729","article-title":"Fluvoxamine but not citalopram increases serum melatonin in healthy subjects: an indication that cytochrome P450 CYP1A2 and CYP2C19 hydroxylate melatonin","volume":"56","author":"von Bahr","year":"2000","journal-title":"Eur J Clin Pharmacol"},{"key":"10.1016\/j.coph.2026.102665_bib57","doi-asserted-by":"crossref","first-page":"540","DOI":"10.1097\/01.jcp.0000095345.32154.9a","article-title":"Effects of sertraline on sleep architecture in patients with depression","volume":"23","author":"Jindal","year":"2003","journal-title":"J Clin Psychopharmacol"},{"key":"10.1016\/j.coph.2026.102665_bib58","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1038\/s41582-020-00435-y","article-title":"Neuroinflammation and microglial activation in Alzheimer disease: where do we go from here?","volume":"17","author":"Leng","year":"2021","journal-title":"Nat Rev Neurol"},{"key":"10.1016\/j.coph.2026.102665_bib59","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1067\/mcp.2000.104071","article-title":"Increased bioavailability of oral melatonin after fluvoxamine coadministration","volume":"67","author":"Hartter","year":"2000","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.coph.2026.102665_bib60","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1016\/j.neuchi.2015.03.002","article-title":"Melatonin: physiological effects in humans","volume":"61","author":"Claustrat","year":"2015","journal-title":"Neurochirurgie"},{"key":"10.1016\/j.coph.2026.102665_bib61","first-page":"451","article-title":"Improvement of cognitive deficits by Sigma-1 receptor agonists: mechanisms and therapeutic implications","volume":"12","author":"Ishima","year":"2014","journal-title":"Curr Neuropharmacol"},{"key":"10.1016\/j.coph.2026.102665_bib62","doi-asserted-by":"crossref","first-page":"596","DOI":"10.1016\/j.cell.2007.08.036","article-title":"Sigma-1 receptor chaperones at the ER-mitochondrion interface regulate Ca2+ signaling and cell survival","volume":"131","author":"Hayashi","year":"2007","journal-title":"Cell"},{"key":"10.1016\/j.coph.2026.102665_bib63","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1016\/j.jphs.2014.11.011","article-title":"The involvement of the Sigma-1 receptor in neurodegeneration and neurorestoration","volume":"127","author":"Ruscher","year":"2015","journal-title":"J Pharmacol Sci"},{"key":"10.1016\/j.coph.2026.102665_bib64","article-title":"Sigma-1 receptor modulation as a therapeutic strategy for neurodegenerative diseases: recent advances","volume":"178","author":"Brimson","year":"2024","journal-title":"Biomed Pharmacother"},{"key":"10.1016\/j.coph.2026.102665_bib65","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1016\/j.pharmthera.2009.07.001","article-title":"The pharmacology of Sigma-1 receptors","volume":"124","author":"Maurice","year":"2009","journal-title":"Pharmacol Ther"},{"key":"10.1016\/j.coph.2026.102665_bib66","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1016\/j.jphs.2014.07.001","article-title":"Sigma-1 receptor: the novel intracellular target of neuropsychotherapeutic drugs","volume":"127","author":"Hayashi","year":"2015","journal-title":"J Pharmacol Sci"},{"key":"10.1016\/j.coph.2026.102665_bib67","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1007\/s00406-021-01326-z","article-title":"Old drug fluvoxamine, new hope for COVID-19","volume":"272","author":"Hashimoto","year":"2022","journal-title":"Eur Arch Psychiatr Clin Neurosci"},{"key":"10.1016\/j.coph.2026.102665_bib68","article-title":"The efficacy and safety of fluvoxamine in patients with COVID-19: a systematic review and meta-analysis from randomized controlled trials","volume":"19","author":"Zhou","year":"2024","journal-title":"PLoS One"},{"key":"10.1016\/j.coph.2026.102665_bib69","first-page":"153","article-title":"Sigma-1 receptors and selective serotonin reuptake inhibitors: clinical implications for neuropsychiatric disorders","volume":"124","author":"Hashimoto","year":"2015","journal-title":"Int Rev Neurobiol"},{"key":"10.1016\/j.coph.2026.102665_bib70","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1007\/164_2017_15","article-title":"Sigma-1 (\u03c31) receptor in memory and neurodegenerative diseases","volume":"244","author":"Maurice","year":"2017","journal-title":"Handb Exp Pharmacol"},{"key":"10.1016\/j.coph.2026.102665_bib71","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1016\/j.pneurobio.2012.09.001","article-title":"Sigma-1 receptor chaperone and brain-derived neurotrophic factor: emerging links in the pathophysiology and treatment of neuropsychiatric disorders","volume":"100","author":"Hashimoto","year":"2013","journal-title":"Prog Neurobiol"},{"key":"10.1016\/j.coph.2026.102665_bib72","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1016\/j.tips.2010.08.007","article-title":"The Sigma-1 receptor chaperone as an inter-organelle signaling modulator","volume":"31","author":"Su","year":"2010","journal-title":"Trends Pharmacol Sci"},{"key":"10.1016\/j.coph.2026.102665_bib73","first-page":"781","article-title":"Sigma-1 receptor ligands in neurodegenerative disorders: current evidence and future therapeutic perspectives","volume":"38","author":"Maurice","year":"2024","journal-title":"CNS Drugs"},{"key":"10.1016\/j.coph.2026.102665_bib74","doi-asserted-by":"crossref","first-page":"733","DOI":"10.3389\/fnins.2019.00733","article-title":"Sigma-1 receptor: evolution of the concept in neuropsychopharmacology","volume":"13","author":"Hayashi","year":"2019","journal-title":"Front Neurosci"},{"key":"10.1016\/j.coph.2026.102665_bib75","first-page":"214","article-title":"Sigma-1 receptors: novel therapeutic targets for neuroprotection and neurorestoration","volume":"8","author":"Maurice","year":"2009","journal-title":"Nat Rev Drug Discov"},{"key":"10.1016\/j.coph.2026.102665_bib76","doi-asserted-by":"crossref","first-page":"1240","DOI":"10.1089\/neu.2021.0355","article-title":"Fluvoxamine confers neuroprotection via inhibiting infiltration of peripheral leukocytes and M1 polarization of microglia\/macrophages in a mouse model of traumatic brain injury","volume":"39","author":"Shi","year":"2022","journal-title":"J Neurotrauma"},{"key":"10.1016\/j.coph.2026.102665_sref77","first-page":"31","article-title":"Clinical efficacy and safety of fluvoxamine in COVID-19 patients: an umbrella review of systematic reviews and meta-analyses","volume":"1","author":"Irfan","year":"2025","journal-title":"Intern Med"},{"key":"10.1016\/j.coph.2026.102665_bib78","doi-asserted-by":"crossref","first-page":"2292","DOI":"10.1001\/jama.2020.22760","article-title":"Fluvoxamine vs placebo and clinical deterioration in outpatients with symptomatic COVID-19: a randomized clinical trial","volume":"324","author":"Lenze","year":"2020","journal-title":"JAMA"},{"key":"10.1016\/j.coph.2026.102665_bib79","doi-asserted-by":"crossref","first-page":"e42","DOI":"10.1016\/S2214-109X(21)00448-4","article-title":"Effect of early treatment with fluvoxamine on risk of emergency care and hospitalization among patients with COVID-19: the TOGETHER randomized platform clinical trial","volume":"10","author":"Reis","year":"2022","journal-title":"Lancet Global Health"},{"key":"10.1016\/j.coph.2026.102665_bib80","article-title":"Viewpoints: sigma-1 receptor agonist fluvoxamine for multiple sclerosis","volume":"37","author":"Hashimoto","year":"2024","journal-title":"Brain Behav Immun Health"},{"key":"10.1016\/j.coph.2026.102665_bib81","first-page":"xxxx","article-title":"Repurposing fluvoxamine for COVID-19 and other disorders through Sigma-1 receptor agonism: pharmacological perspectives","volume":"24","author":"Hashimoto","year":"2023","journal-title":"Int J Mol Sci"}],"container-title":["Current Opinion in Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1471489226000615?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1471489226000615?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,9,17]],"date-time":"2026-09-17T07:15:17Z","timestamp":1789629317000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1471489226000615"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,12]]},"references-count":81,"alternative-id":["S1471489226000615"],"URL":"https:\/\/doi.org\/10.1016\/j.coph.2026.102665","relation":{},"ISSN":["1471-4892"],"issn-type":[{"value":"1471-4892","type":"print"}],"subject":[],"published":{"date-parts":[[2026,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Pharmacological insights into fluvoxamine maleate: \u03c31 receptor agonism, multimodal mechanisms, and therapeutic repositioning","name":"articletitle","label":"Article Title"},{"value":"Current Opinion in Pharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.coph.2026.102665","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier Ltd. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"102665"}}